Add Row
Add Element
Tech Life Journal
update
Tech Life Journal 
update
Add Element
  • Home
  • Categories
    • Innovation
    • Digital Tools
    • Smart Living
    • Health Tech
    • Gear Review
    • Digital Life
    • Tech Travel
    • Voices in Tech
  • Featured
December 12.2025
3 Minutes Read

Unlocking Healthcare Potential: Why Migrating EHRs to the Cloud Matters

Healthcare professional managing EHRs on a clinic computer.

Harnessing the Cloud: A Transformative Leap for Healthcare

The shift of electronic health records (EHRs) to cloud computing is more than just a technological upgrade; it's a transformative leap for healthcare organizations, allowing them to streamline processes and enhance patient care. As Jeffrey Thomas, CTO of Sentara Health, emphasizes, this migration isn’t mere data relocation but a re-engineering of healthcare workflows that fosters greater efficiency and adaptability in a landscape where technological innovation is crucial.

A Strategic Approach to Cloud Migration

Sentara Health's journey is a compelling case study in successful EHR cloud migration. Starting in 2018, Sentara embraced a thoughtful strategy, moving only about 550 out of 1,300 existing applications to cloud platforms. This selective migration aimed to reduce complexity and eliminate redundant processes that can hamper performance. By avoiding a simple 'lift-and-shift' method, organizations can ensure they are not carrying over past inefficiencies into their new cloud-based systems.

Thomas advises that organizations should think beyond the initial migration day. “The hardest thing is day two and beyond,” he states, indicating the importance of ongoing cultural and operational shifts in IT management that accompany the transition. Embracing agile methodologies and ensuring that both operations and security teams work collaboratively can break down the silos that often stifle innovation in healthcare technology.

The Cultural Shift: Embracing Change

One of the primary challenges in such a transition is the cultural change required within IT departments. Sentara Health worked diligently to foster a collaborative environment, integrating agile and DevOps approaches that encourage teamwork across departments. “It changed how we work in IT,” Thomas explains, highlighting the need for buy-in from all levels of staff, from clinicians to administration. Without this cultural transformation, healthcare systems risk creating disconnected operations that detract from the cloud’s benefits.

Kees Hertogh from Microsoft stresses that organizations must manage change effectively by communicating to stakeholders the 'why' behind cloud adoption. A clear roadmap, combined with celebrations of early achievements, can help build confidence and support within an organization.

Benefits Beyond the Migration

Once the initial hurdles are overcome, the benefits of cloud-based EHR systems become evident. Users, both patients and providers, can engage with records via multiple devices, enhancing accessibility and communication. This agility allows healthcare professionals to respond to patient needs more efficiently, whether they are in a hospital, clinic, or working remotely. Enhanced patient care extends beyond emergency responses; it encompasses ongoing relationship management through interactive online platforms.

Financially, cloud systems provide a shift in capital expenditure to a more predictable operating expense model, allowing organizations to align spending with actual usage. This flexibility can be crucial as healthcare demands evolve, enabling quick scaling of resources without the burden of costly hardware purchases.

The Future of EHR and Cloud Computing

Looking ahead, it’s vital to recognize that EHR cloud migration is part of a larger trend in healthcare digital transformation. The projected growth in the EHR cloud market highlights a growing recognition of its importance. Innovations such as predictive analytics, remote patient monitoring, and AI capabilities promise to revolutionize how care is delivered and managed.

As discussed in the comprehensive guide for EHR cloud migration, investing in a robust cloud infrastructure goes beyond immediate benefits. It prepares organizations to integrate future advancements seamlessly, ensuring that they remain competitive in a rapidly evolving digital landscape.

Final Thoughts

The journey to migrating EHRs to cloud computing is one marked by significant challenges, yet the rewards can be transformative. For healthcare administrators and IT leaders, it’s essential to approach this migration with a commitment to ongoing cultural and operational change, as this is where true success lies. Those venturing forward into the cloud should view it not just as a technology upgrade, but as an opportunity to rethink and reshape the way care is delivered, enhancing patient experience and organizational efficiency alike.

Health Tech

0 Comments

Write A Comment

*
*
Related Posts All Posts
02.24.2026

The Galleri Cancer Blood Test: A Major Setback in Early Detection

Update The Reality Behind Multi-Cancer Testing In a significant setback for the field of cancer early detection, the Galleri blood test, developed by the biotech company Grail, has failed to meet its primary goal in a major clinical trial conducted in the UK. This blood test aimed at detecting up to 50 types of cancer by identifying tiny fragments of tumor DNA in the bloodstream was closely watched by both researchers and investors alike, hoping it would usher in a new era in preventive oncology. Trial Highlights: What Went Wrong? The trial involved over 142,000 healthy adults aged 50 to 77, running for three years under the umbrella of the UK's National Health Service (NHS). Despite earlier optimism, the results revealed no significant reduction in late-stage cancer diagnoses among those who took the test compared to those who did not. Grail's target was a 20% decrease in advanced cancers, a benchmark the findings fell short of. Dr. Richard Houlston of the Institute of Cancer Research stated, "This doesn't support rollout within the American health care system," emphasizing the critical need for demonstrable benefits in early detection tests. The Flicker of Hope: Stage Four Cancers While the study's primary endpoint was missed, some experts pointed to a slight decline in Stage 4 cancer diagnoses. According to Grail, the number of Stage 4 cancers detected did fall by about 20%, hinting at a potential early detection of more aggressive cancers. However, this has been described as 'speculative' by many researchers who remain cautious in their optimism. Prof. Charles Swanton, leading the trial, expressed a measured excitement about these findings, noting their importance in oncological practice. The Broader Implications for Early Detection Experts widely agree that the failure of this trial doesn't completely negate the value of blood tests in cancer screening, particularly for cancers without established early detection methods. However, ongoing apprehensions linger about the accuracy and reliability of such tests. False positives can lead to needless anxiety and invasive procedures, demonstrating that while early detection is crucial, it must also be effective and reliable. Financial Fallout for Grail The announcement of Galleri’s failure to meet trial objectives had immediate repercussions for Grail’s market position, halving its share value. As nearly all of the company’s revenue hinges on Galleri sales, this financial downturn poses serious questions about the future of their operations, especially since they have yet to receive FDA approval for the test. Given that insurance often does not cover the cost of Galleri, which is set at $949, securing a supportive regulatory environment is essential for the sustainability of the test. The recent law permitting Medicare coverage of some cancer detection tests may provide a lifeline, but Galleri is not automatically included, raising the stakes significantly. What Lies Ahead for Cancer Screening? The initial enthusiasm surrounding multi-cancer blood tests like Galleri has been met with sobering realizations. While it’s clear that cancer detection technology is evolving, just how effective these technologies will prove to be remains uncertain. As the NHS and medical communities assess the trial's full data, one crucial question emerges: Can we continue to develop reliable screening tools that significantly contribute to reducing mortality from various cancers? Understanding the Bigger Picture It's essential to recognize that early detection is only one aspect of cancer treatment. Successful treatment outcomes also depend on the availability of effective therapies and the personalized approach taken by healthcare providers. Although the results from the Galleri trial are disappointing, they underscore the ongoing challenge of improving cancer care through science and innovation. In conclusion, while Galleri's recent failure raises important concerns, the journey towards effective cancer screening is far from over. Stakeholders in the health sector must continue to advocate for sound research practices and patient safety, ensuring that any emerging technology is both effective and beneficial for patients.

02.24.2026

Unlocking the Future: Why a Tech-Empowered Workforce in Healthcare Starts with Nursing Insights

Update The Evolution of Nursing in a Tech-Enabled WorldAs the healthcare landscape evolves, nursing professionals are increasingly at the forefront of technological integration. The ongoing ViVE 2026 conference highlights significant conversations surrounding the role of technology in nursing. Expert discussions underscore a pressing reality: many digital solutions aimed at enhancing patient care lack essential insights from nurses themselves. This absence can lead to inefficiencies and missed opportunities for improving patient outcomes.Learning from Frontline ExperiencesSpeakers like Tonychris Nnaka at the conference emphasize the critical need for nursing input in the development of healthcare technologies. "If you are trying to design something that really can be implemented across a healthcare system, especially in the clinical setting, it is crucial that you have a nurse at the table," Nnaka stated. This echoes a broader sentiment observed across various healthcare forums regarding the necessity of incorporating frontline perspectives in tech developments.Navigating Tech Adoption ChallengesThe adoption of artificial intelligence and automated documentation tools faces hurdles, largely due to a misunderstanding of nursing workflows. Susan Grant, who now leads clinical operations at symplr, advocates for better preparation among nurse leaders to engage in technology conversations effectively. "We need to upskill ourselves. If we’re going to be at the table, we have to be prepared to have the dialogue," she urges. This proactive approach is essential to bridge the gap between nursing practice and technological advancements.The Future of Nursing: Collaborate or Get Left BehindTechnology companies are being called to establish partnerships that truly respect the complexities of nursing roles. Bonnie Clipper, founder of the Virtual Nursing Academy, puts it bluntly: technology must not reduce nursing to mere AI or chatbots. "We’re looking for partners that want to work with us, partners that want to understand what nursing brings to the table," she asserted. This collaborative mindset is necessary not just for the continued relevance of nursing in the tech sphere but also for the enhancement of patient care.Insights and Actions for Healthcare LeadersThe discussions at ViVE 2026 serve as a catalyst for healthcare leaders to reassess their technology strategies. With workforce stresses like shortages and burnout looming large, the integration of nurse insights into technology development can help mitigate these challenges. Additionally, embracing innovations like virtual nursing and AI governance will be crucial as healthcare models continue to evolve.

02.23.2026

Blood Test Reveals Alzheimer's Risk With 94.5% Accuracy

Update Revolutionizing Alzheimer’s Diagnosis with a Simple Blood Test Recent clinical studies have unveiled remarkable advancements in diagnosing Alzheimer's disease, achieving a diagnostic accuracy of 94.5% through a simple blood test. This breakthrough discovery originated from research conducted by a team in Spain, targeting the p-tau217 protein, a biomarker associated with Alzheimer’s progression. By tracking this protein through blood samples, medical professionals can now diagnose Alzheimer’s with much higher confidence and accuracy compared to traditional methods. The Science Behind p-tau217 The protein p-tau217 is a biomarker that indicates changes in the brain associated with Alzheimer’s. It assists in evaluating the pathological processes affecting neurons. In this recent study, doctors initially diagnosed Alzheimer’s using standard clinical evaluations, with an accuracy rate of only 75.5%. However, when they incorporated results from the p-tau217 blood test, diagnostic accuracy surged by 19%, significantly enhancing clinicians' confidence in their diagnoses. The average confidence score rose from 6.9 to 8.49 on a ten-point scale, showcasing an impressive increase in trust towards the test results. Why Blood Testing Matters for Early Detection Detecting Alzheimer’s at the earliest stages is crucial, as it may allow for more effective intervention strategies. Current diagnostic practices often involve costly and invasive procedures like brain scans and spinal taps. The study’s findings indicate that blood tests can serve as a more accessible and practical alternative. Elevated p-tau217 levels in the blood have emerged as reliable early indicators of Alzheimer's, promising a future where diagnosing the disease will be less cumbersome, costly, and intimidating for patients. Global Implications of This Blood Test The implications of this research extend far beyond the walls of medical clinics in Spain. With the aging global population, the prevalence of age-related diseases like Alzheimer’s is on the rise. Current tools for diagnosis are insufficient, often leading to misdiagnoses and delayed treatment. With the establishment of simple blood tests, healthcare systems could adopt more streamlined and effective methods for early detection, potentially impacting millions of lives around the world. Comparative Analysis With Previous Research Earlier studies have shown promise in blood testing for Alzheimer’s detection, but the advent of p-tau217 may represent a pivotal moment in Alzheimer's research. Previous methods of detection from cerebrospinal fluid or PET scans provided partial insights into the presence of biomarkers, yet they came with high costs and discomfort for patients. Recent advancements illustrate that relying on blood tests can dramatically shift the standard care model, promoting preventive healthcare. The Road Ahead: Implementing The Blood Test While this groundbreaking study represents a leap forward, the implementation of blood tests in routine clinical practice is still in its infancy. Challenges remain regarding defining thresholds for ‘normal’ versus ‘high’ levels of p-tau217 in the blood, alongside ensuring that further validation studies reinforce its reliability beyond the initial clinical setting. Nonetheless, as Alzheimer's research advances and trials continue, there is optimism that widespread screening for Alzheimer’s can soon become a reality, allowing for more timely and effective interventions.

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*